Shire plc envisions FBS0701 from FerroKin BioSciences Inc. as the backbone of a new commercial hematology unit within its specialty pharmaceuticals business.

Last month, Shire said it will acquire FerroKin for $100 million up front plus up to $225 million in development, regulatory and sales milestones.